Cytokines in Bladder Pain Syndrome: A Review of the Literature

Introduction and hypothesis Bladder pain syndrome (BPS) is poorly understood with both the aetiology and pathophysiology being unknown. Symptoms overlap with other disorders, such as overactive bladder (OAB) and chronic pelvic pain disorders such as endometriosis, making a consensus on how to diagnosis and manage patients challenging. The development of biomarkers for BPS may be the key to understanding more about its pathophysiology, as well as aiding diagnosis, subclassification, and discovering new drug targets for its management. As inflammation is widely understood to hold a central role in BPS, the evaluation of cytokines has gained interest. This article summarises the current literature and understanding of urinary, serum, and bladder tissue cytokines found elevated in patients with bladder pain syndrome.

literature search using Pub Med with the keywords “bladder pain syndrome”, “painful bladder syndrome”, “bladder pain”, “Interstitial cystitis” AND “cytokines” or “inflammation”. This study was except from institutional approval.

Thirty-six cytokines have been identified as being statistically significantly elevated in either the serum, urine, or bladder tissue of patients with bladder pain syndrome in the 22 studies identified in this review of the literature. These cytokines include those from the interleukin group (n = 14), the CXC chemokine group (n = 5), and the C–C chemokine group (n = 7).

CXCL-1, CXCL-8, CXCL-9, CXCL-10, CXCL-11 from the CXC chemokine group, and CCL2, CCL4, CCL5, CCL7, and CCL11 from the C–C chemokine group have been found to be significantly elevated in patients with bladder pain in the literature. Many of these analytes also have supporting evidence for their roles in bladder pain from animal models and studies in other chronic inflammatory conditions. It is likely that a single cytokine will not serve as an adequate biomarker of disease in bladder pain syndrome for either diagnosis or disease severity. Instead, panels of inflammatory mediators may reveal more about the different pathways of inflammation leading to similar presentations of bladder pain in patients. Similar content being viewed by others

Doggweiler R, Whitmore KE, Meijlink JM, Drake MJ, Frawley H, Nordling J, Hanno P, Fraser MO, Homma Y, Garrido G, Gomes MJ, Elneil S, van de Merwe JP, Lin ATL, Tomoe H. A standard for terminology in chronic pelvic pain syndromes: A report from the chronic pelvic pain working group of the international continence society. Neurourol Urodyn. 2017;36(4):984–1008. https://doi.org/10.1002/nau.23072. Konkle KS, Berry SH, Elliot MN, et al. Comparison of an interstitial cystitis/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology study. J Urol. 2012;187(2):508–12. Anger JT, Zabihi N, Clemens JQ, Payne CK, SaigalRodriguez CSIV. Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome. Int Urogynaecol J Pelvic Floor Dysfunct. 2011;22(4):395–400. Tirlapur SA, Khan KS. An assessment of clinicians’ and patients’ experiences in the management of bladder pain syndrome. J Obstet Gynaecol. 2016;36:241–5. Hunner GL. A rare type of bladder ulcer in women, report of cases. Boston Med Surg J. 1915;172(18):660–4. Jones CA, Nyberg L. Epidemiology of interstitial cystitis. Urology. 1997;49(supplement 5):2–9. Abrams PH, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Standardisation Sub-committee of the International Continence Society, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–78. Dinis S, De Oliveira JT, Pinto R, Cruz F, Buffington CT, Dinis P. From bladder to systemic syndrome: concept and treatment evolution of interstitial cystitis. Int J Womens Health. 2015;7:735–44. Gamper M, Regauer S, Welter J, Eberhard J, Viereck V. Are mast cells still good biomarkers for bladder pain syndrome/ interstitial cystitis? J Urol. 2015;193(6):1994–2000. Ackerman AL, Lee UJ, Jellison FC, et al. MRI suggests increased tonicity of the levator ani in women with interstitial cystitis/ bladder pain syndrome. Int Urogynaecol J. 2015. https://doi.org/10.1007/s00192-015-2794-6. Sant GR, Kempuraj D, Marchand JE, Theoharides TC. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology. 2007;69(supplement 4):34–40. Oshea JJ, Murray PJ. Cytokine signalling modules in inflammatory responses. Immunity. 2008;28:477. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 2009;78:539. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329. Monastero RN, Pentyala S. Cytokines as biomarkers and their respective cutoff levels. Int J Inflamm. 2017;2017:4309485. Bhangoo S, Ren D, Miller RJ, et al. Delayed functional expression of neuronal chemokine receptors following focal nerve demyelination in the rat: a mechanism for the development of chronic sensitisation of peripheral nocicetors. Mol Pain. 2007;3:38. Jiang YH, Peng CH, Liu HT, Kuo HC. Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis/bladder pain syndrome. PLoS One. 2013;8(10):e76779. https://doi.org/10.1371/journal.pone.0076779. eCollection 2013. Corcoran Y, Tyagi J, Leng T. Mapping the cytokine profile of painful bladder syndrome/ interstitial cystitis in human bladder and urine specimens. Orld J Urol. 2013;31(1):241–6. https://doi.org/10.1007/s00345-012-0852-y. Tyagi P, Killinger K, Tyagi V, Nirmal J, Chancellor M, Peters K. Urinary chemokines as non-invasive predictors of ulcerative interstitial cystitis. J Urol. 2012;187(6):2243–8. https://doi.org/10.1016/j.juro.2012.01.034. Jiang YH, Jhang JF, Hsu YH, Kuo HC. Usefulness of urinary biomarkers for assessing bladder condition and histopathology in patients with interstitial cystitis/bladder pain syndrome. Int J Mol Sci. 2022;23:12044. Luster AD, Cardiff RD, MacLean JA, Crowe K, Granstein RD. Delayed wound healing and disorganized neovascularization in transgenic mice expressing the IP-10 chemokine. Proc Assoc Am Physicians. 1998;110(3):183–96. Schrepf A, O’Donnell M, Luo Y, Bradley CS, Kreder K, Lutgendorf S, Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. Inflammation and inflammatory control in interstitial cystitis/bladder pain syndrome: associations with painful symptoms. Pain. 2014;155(9):1755–61. https://doi.org/10.1016/j.pain.2014.05.029. Logadottir Y, Delbro D, Fall M, Gjertsson I, Jirholt P, Lindholm C, Peeker R. Cytokine expression in patients with bladder pain syndrome/interstitial cystitis ESSIC type 3C. J Urol. 2014;192(5):1564–8. https://doi.org/10.1016/j.juro.2014.04.099. Moldwin RM, Nursey V, Yaskiv O, Dalvi S, Macdonald EJ, Funaro M, Zhang C, DeGouveia W, Ruzimovsky M, Rilo HR, Miller EJ, Najjar S, Tabansky I, Stern JNH. Immune cell profiles of patients with interstitial cystitis/bladder pain syndrome. J Transl Med. 2022;20(1):97. https://doi.org/10.1186/s12967-022-03236-7. Lamb LE, Janicki JJ, Bartolone SN, Peters KM, Chancellor MB. Development of an interstitial cystitis risk score for bladder permeability. PLoS One 2017;12(10):e0185686. https://doi.org/10.1371/journal.pone.0185686. eCollection 2017. Akiyama Y, Miyakawa J, O’Donnell MA, Kreder KJ, Luo Y, Maeda D, Ushiku T, Kume H, Homma Y. Overexpression of HIF1α in hunner lesions of interstitial cystitis: pathophysiological implications. J Urol. 2022;207(3):635–46. https://doi.org/10.1097/JU.0000000000002278. Furuta A, Yamamoto T, Suzuki Y, Gotoh M, Egawa S, Yoshimura N. Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder. Int Urogynaecol J. 2017. https://doi.org/10.1007/s00192-017-3547-5. Niimi A, Igawa Y, Aizawa N, Honma T, Nomiya A, Akiyama Y, Kamei J, Fujimura T, Fukuhara H, Homma Y. Diagnostic value of urinary CXCL10 as a biomarker for predicting Hunner type interstitial cystitis. Neurourol Urodyn. 2018;37(3):1113–9. https://doi.org/10.1002/nau.23431. Ogawa T, Homma T, Igawa Y, Seki S, Ishizuka O, Imamura T, Akahane S, Homma Y, Nishizawa O. CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. J Urol. 2010;183(3):1206–12. https://doi.org/10.1016/j.juro.2009.11.007. Abdel-Mageed AB, Bajwa A, Shenassa BB, Human L, Ghoniem GM. NF-kappaB-dependent gene expression of proinflammatory cytokines in T24 cells: possible role in interstitial cystitis. Urol Res. 2003;31(5):300–5. https://doi.org/10.1007/s00240-003-0339-9. Jiang J, Hsu Ho, Wu K. Urine cytokines as biomarkers for diagnosing interstitial cystitis/bladder pain syndrome and mapping its clinical characteristics. Am J Physiol Renal Physiol. 2020;318:F1391–9. https://doi.org/10.1152/ajprenal.00051.2020. Jiang YH, Jhang JF, Hsu YH, Ho HC, Wu YH, Kuo HC. Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm. Int J Mol Sci. 2022;23(19):12044. https://doi.org/10.3390/ijms231912044. Shen YC, Tyagi P, Lee WC, Chancellor M, Chuang YC. Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo. Sci Rep. 2021;11(1):7558. https://doi.org/10.1038/s41598-021-87040-1. Jiang C, Xu M, Zhu J, Yang D, Xue B. CircTHBS1 facilitates the progression of interstitial cystitis depending on the regulation of miR-139-5p/MFN2 axis. Drug Dev Res. 2022;83(2):351–61. https://doi.org/10.1002/ddr.21864. Jiang YH, Kuo YC, Jhang JF, Lee CL, Hsu YH, Ho HC, Kuo HC. Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis. Sci Rep. 2020;10(1):15218. https://doi.org/10.1038/s41598-020-72292-0. Abernethy MG, Rosenfeld A, White JR, Mueller MG, Lewicky-Gaupp C, Kenton K. Urinary microbiome and cytokine levels in women with interstitial cystitis. Obstet Gynecol. 2017;129(3):500–6. https://doi.org/10.1097/AOG.0000000000001892. Soriano A, Andy U, Hassani D, Whitmore K, Harvie H, Malykhina AP, Arya L. Relationship of bladder pain with clinical and urinary markers of neuroinflammation in women with urinary urgency without urinary incontinence. Female Pelvic Med Reconstr Surg. 2021;27(2):e418–22. https://doi.org/10.1097/SPV.0000000000000951. Lamale LM, Lutgendorf SK, Zimmerman MB, Kreder KJ. Interleukin-6, histamine, and methylhistamine as diagnostic markers for interstitial cystitis. Urology. 2006;68(4):702–6. https://doi.org/10.1016/j.urology.2006.04.033. Douglas IS, Nicolls MR. Chemokine-mediated angiogenesis: an essential link in the evolution of airway fibrosis? J Clin Invest. 2005;115:1133–6. Mantovani A, Sica A, Sizzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarisation. Trands Immunol. 2004;25:677–86. Antoniou KM, Tzanakis N, Tzortzaki EG, et al. Different angiogenic CXC chemokine levels in bronchoalveolar lavage fluid after interferon gamma-1b therapy in indiopathic pulmonary fibrosis patients. Pulm Pharmacol Ther. 2008;21:840. Sakthivel SK, Singh UP, Singh S, et al. CXCL10 blockade protects mice from cyclophosphamide-induced cystitis. J Immune Based Ther Vaccines. 2008;6:6. Singh S, Anshita D, Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol. 2021;101:107598. Grimm MC, Elsbury SK, Pavli P, Doe WF. Enhanced expression and production of monocyte chemoattractant protein-1 in inflammatory bowel disease mucosa. J Leukoc Biol. 1996;59(6):804–12. Harigai M, Hara M, Yoshimura T, Leonard EJ, Inoue K, Kashiwazaki S. Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol. 1993;69(1):83–91. Lee YH, Song GG. Urinary MCP-1 as a biomarker for lupus nephritis: a metaanalysis. Z Rheumatol. 2017;76(4):357–63. Dansereau MA, Gosselin RD, Pohl M, et al. Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonistic-treated rats. J Neurochem. 2008;106(2):757–69. Tanaka M, Nakagawa S. Enhanced production of monocyte chemosattractant protein-1 in the dorsal root ganglia in a rat model of neuropathic pain: possible involvement in the development of neuropathic pain. Neurosci Res. 2004;48(4):463–9. Abbadie C, Lindia JA, Cumiskey AM, et al. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci U S A. 2003;100(13):7947–52. Arms G, Malley V. Expression and function of CCL2/CCR2 in rat micturition reflexes and somatic sensitivity with urinary bladder inflammation. Am J Physiol. 2013;305(1):F111–22. Li Y, Yao J, Han C, et al. Quercetin, inflammation and immunity. Nutrients. 2016;8(3):167. https://doi.org/10.3390/nu8030167. Jiang M, Wang K, Huang Y, Zhang X, Yang T, Zhan K, Zhao G. Quercetin alleviates lipopolysaccharide-induced cell oxidative stress and inflammatory responses via regulation of the TLR4-NF-κB signalling pathway in bovine rumen epithelial cells. Toxins (Basel). 2023;15(8):512. Chen K, Gregory K. RANTES mediate TNF-dependent lamina propria mast cell accumulation and barrier dysfunction in neurogenic cystitis. Am J Physiol Renal hysiol. 2007;292(5):F1372–9. https://doi.org/10.1152/ajprenal.00472.2006. Wakabayashi K, Isozaki T, Tsubokura Y, Fukuse S, Kasama T. Eotaxin1/CCL11 is involved in cell migration in rheumatoid arthritis. Sci Rep. 2021;11(1):7937. https://doi.org/10.1038/s41598-021-87199-7. Rankin SM, Conroy DM, Williams TJ. Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today. 2000;6(1):20–7. https://doi.org/10.1016/s1357-4310(99)01635-4. Erickson DR, Tomaszewski JE, Kunselman AR, Stetter CM, Peters KM, Rovner ES, Demers LM, Wheeler MA, Keay SK. Urine markers do not predict biopsy findings or presence of bladder ulcers in interstitial cystitis/ painful bladder syndrome. J Urol. 2008;179(5):1850–6. https://doi.org/10.1016/j.juro.2008.01.047. Ozaki K, Leonard W. Cytokine and cytokine receptor pleiotrophy and redundancy. J B Chem. 2002;277(33):29355–8. Oliver JC, Bland LA, Oettinger CW, Arduino MJ, Mcallister SK, Aguero SM, Favero MS. Lymphokine Cytokine Res. 1993;12:115. Panicker G, Meadows KS, Lee DR, Nisenbaum R, Unger ER. Cytokine. 2007;37:176. Friebe A, Volk H. Arch Pathol Lab Med. 2009;132:1802. Cohen L, Keegan A, Melanson SEF, Walt DR. Clin Biochem. 2019;65:38. Author information Authors and Affiliations Contributions Vik Khullar: Consultant for Abbvie, acceptance of paid travel expenses or honoraria from GSK. Lemmon, Bernadette: literature search, writing and editing of manuscript. Kyrgiou, Maria: writing and editing of manuscript. Mullins, Edward: writing and editing of manuscript. Khullar, Vikram: writing and editing of manuscript. Corresponding author Ethics declarations Conflicts of Interest None. Additional information Handling Editor: Gin-Den Chen Editor in Chief: Kaven Baessler Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Brief Summary Literature review of cytokines in the urine, serum, and bladder tissue of those with bladder pain syndrome. Rights and permissions About this article Cite this article Lemmon, B., Kyrgiou, M., Mullins, E. et al. Cytokines in Bladder Pain Syndrome: A Review of the Literature. Int Urogynecol J 35, 1119–1129 (2024). https://doi.org/10.1007/s00192-024-05778-4 Received: Accepted: Published: Version of record: Issue date: DOI: https://doi.org/10.1007/s00192-024-05778-4